Skip to content
drillr.ai
Sign up

02162.HK

Keymed Biosciences Inc.

HKSE · Healthcare · Biotechnology · CN

HKD 67.05
+0.22%
Ask drillr

  • Oct 28, 2026, 04:32 UTC

    Keymed Biosciences, Inc. shares fell 14.4% on October 27.

    Source:

  • Oct 28, 2026, 04:32 UTC

    ASTRAZENECA PLC presented positive full-analysis data for sone-ve in the CLARITY-Gastric01 trial at ESMO 2026 on October 27.

    Source:

  • Oct 27, 2026, 08:12 UTC

    Hong Kong-listed shares showed mixed moves, including Xiaomi Corp. falling 4.6% and China Construction Bank, CK Infrastructure and H&H International Holdings reaching record highs.

    Source:

  • Oct 27, 2026, 04:12 UTC

    Hong Kong-listed shares showed varied moves at midday, including Xiaomi Corp. down 4.2%, Lenovo Group Ltd. up 5.8%, and Duality Biotherapeutics, Inc. down 29.4%.

    Source:

  • Sep 21, 2026, 02:51 UTC

    Hong Kong-listed innovative pharmaceutical stocks rose, with Akeso up 7.9% to HK$97.65, GenScript Biotech up 4.68% to HK$41.18, and other Chinese biopharma shares posting gains of over 7% to 9%.

    Source:

  • Sep 21, 2026, 02:12 UTC

    Hong Kong-listed biopharmaceutical stocks rallied broadly on September 21, with Shanghai Henlius Biotech up over 10%, Junshi Biosciences and Akeso up over 8%, Keymed Biosciences and InnoCare Pharma up over 7%, and RemeGen, GenScript Biotech, WuXi Biologics and Kelun-Biotech up over 6%.

    Source:

  • Sep 2, 2026, 13:08 UTC

    Kangnuo-B signed an exclusive licensing agreement with Aeira Pte. Ltd. for the registration and commercialization of its self-developed Stapokibart injection (Kangyueda) in 18 countries and regions in Southeast Asia and Central Asia.

    Source:

  • Sep 1, 2026, 03:03 UTC

    KeyBanc Capital Markets raised its price target on Keysight Technologies to $210 from $195 and maintained an Overweight rating, citing strong demand for AI-related testing solutions.

    Source:

  • Aug 31, 2026, 23:17 UTC

    China's 2026 National Essential Medicines List took effect on September 1, adding 116 new drugs including four domestic Class 1 innovative drugs and Novo Nordisk's semaglutide.

    Source:

  • Aug 20, 2026, 01:34 UTC

    KeyMed Biosciences reported interim results for the six months ended June 2026, with revenue of RMB 617 million, up 24% year-on-year, and a net profit of RMB 1.218 billion, turning around from a loss of RMB 78.79 million in the same period last year.

    Source:

  • Jul 23, 2026, 04:27 UTC

    China's National Medical Products Administration (NMPA) Drug Evaluation Center included CM512 (TSLP/IL-13 bispecific antibody) of Kangnuoya-B (02162) into the Breakthrough Therapy Designation list for treating chronic rhinosinusitis with nasal polyps (CRSwNP).

    Source: